Today, the Elixinol share price was trading down initially but was able to register a small uptick when the announcement was released, and then settled where it started at $4.As per the announcement, the Manufacture licence allows Elixinol’s subsidiary to manufacture...
Syrah Resources Limited [ASX:SYR] is the most shorted stock on the ASX. We take a look at the Syrah Resources share price, quarterly report and assess whether or not it is a bargain at this price.
After a brief retracement following the escalation of trade war tensions, the Lynas [ASX:LYC] share price has begun to rise again. We look at two recent developments in the world of rare earth mining and give our take on the outlook for Lynas.
It remains one of the most shorted stocks on the ASX, indicating that there are some large bets on a further decline. Today, we look at the highlights from Galaxy Resources’ quarterly update and have a look at why interest in lithium has waned. We conclude by looking at nickel’s prospects.
Some interesting things happened in the world of Australian uranium stocks today. We look at the Trump effect.
With more than 7% of AMP shares [ASX:AMP] on issue being short sold — it appears many are still betting against the company. We look at the aborted Resolution Life sale and AMP’s decision to not offer an interim dividend.
Today, we look at Myer Holdings Limited [ASX:MYR] efforts to re-jig the business and the impact of buy now-pay later services like Afterpay and Zip. Our conclusion is that Myer shares are potentially cheap, depending on your investment horizon.
It has been a tough year for the MMJ share price [ASX:MMJ], with it losing just over 20% of its value. Let’s look at a few reasons why the company could start trending up over the coming months.
The company’s most recent announcement was a conference call transcript, where CEO Andrew Penn provided an update on their progress towards the T22 goals. Perhaps the most interesting question in this conference call was from JP Morgan’s Eric Pan, who discussed Telstra property sales.
The share price of Neuroscientific Biopharmaceuticals Ltd [ASX:NSB] is up a massive 175.86% trading at 40 cents following the end of its trading halt - the company announced today ‘breakthrough’ results for its Alzheimer’s drug and investors were clearly excited.